Sleep Became a Product Category Worth Billions. The Treatment With the Best Evidence Isn't for Sale.

The market-sizing figures vary by firm because there is no single agreed definition of what counts as sleep tech. Straits Research puts the global sleep-tech market at $23.35 billion in 2025, growing to $65.69 billion by 2033. A separate estimate puts the broader sleep-tech devices category at $29.3 billion in 2025, projected to reach $134.7 billion by 2034. Polaris Market Research sizes the global sleeping aids and supplement market, which includes melatonin and other over-the-counter sleep products, at $92.39 billion in 2025. The mattress industry, a more mature and directly comparable category, was valued at roughly $47 billion to $49 billion globally in 2025, with the smart-mattress segment specifically, adjustable firmness, cooling, built-in tracking, estimated near $1.8 billion and growing faster than the category overall. These are industry estimates rather than audited figures, and should be read as directional, but the direction is consistent across every firm: expansion, year over year, across every product type sold as a sleep fix.

Those two regulatory facts are the actual mechanism connecting a growing market to a flat outcome. Under the 1994 Dietary Supplement Health and Education Act, a company selling a melatonin gummy can market it with structure-or-function language, such as supports restful sleep, without running a clinical trial, because the law does not authorize the FDA to demand proof of effectiveness before a supplement reaches shelves; the agency can only act after the fact, against products already found unsafe or mislabeled. Separately, the FDA's general wellness policy, most recently updated in January 2026, names sleep and activity trackers as low-risk products it does not intend to regulate as medical devices, on the condition that they do not claim to diagnose a condition such as sleep apnea. A ring reporting a nightly readiness score or a REM sleep breakdown operates inside that exemption; the moment a device claims to diagnose rather than track, it faces the far heavier evidentiary bar medical devices carry. Nearly every consumer sleep product on the market today stays on the light side of that line, the side that requires no independent proof the underlying metric is accurate.

Set against that is what sleep medicine's own clinical guideline actually recommends, and the contrast with what gets marketed is direct. The AASM's 2021 clinical practice guideline, built on a systematic review graded using the GRADE methodology, gives its strongest recommendation to cognitive behavioral therapy for insomnia, a structured behavioral treatment typically delivered across four to eight sessions that combines sleep education with specific techniques like stimulus control and sleep restriction. Between 50 and 75 percent of patients who complete it see clinically significant improvement, with benefits, including roughly a 30 percent increase in slow-wave sleep, holding up at six-month follow-up. None of that is a product in the conventional sense. It is a course of guided behavior change, harder to package, harder to ship, and dependent on access to a trained provider, which is exactly the kind of thing a retail or app-store business model struggles to sell at scale. The guideline goes further than simply omitting products from its top recommendation. It directly states that sleep hygiene education, tips about light, temperature, caffeine timing, and bedroom setup, the exact category most sleep-environment products implicitly sell, should not be used as a stand-alone therapy for chronic insomnia. The advice is not wrong. It is, according to the body that sets clinical guidelines, simply not enough by itself, which is a different claim than the one implied by a product marketed as a sleep fix.

Supplement makers benefit most directly from the regulatory structure: melatonin sales roughly tripled between 2016 and 2020 without any accompanying change in clinical evidence about what the hormone does for adult insomnia, and the law governing supplements means a company faces no obligation to prove a bottle works before selling it, only to avoid provable harm after the fact. Wearable makers benefit from a parallel gap: a device can imply clinical-grade insight, sleep-stage breakdowns, readiness scores, recovery metrics, while staying inside the FDA's low-risk general wellness exemption by avoiding any explicit diagnostic claim. Mattress companies benefit from a category where individual fit is genuinely hard for a shopper to evaluate without lying on the product for weeks, which makes premium smart features easy to sell as a proxy for a claim, better sleep, that is difficult for any individual buyer to disprove inside a return window.

The people worse off are concrete, not abstract. CDC's report on pediatric melatonin ingestions found a 530 percent increase in poison control calls between 2012 and 2021, rising from about 8,300 to more than 52,000 cases a year, with 4,097 hospitalizations, 287 intensive care admissions, and two deaths, both children under two, over that period; the report ties the rise directly to melatonin's much wider availability and to gummies specifically, which children can mistake for candy. Separately, Baron and colleagues' 2017 case series, which coined the term orthosomnia, describes a different kind of harm: patients who arrived at a sleep clinic not with a diagnosable disorder but with a fixation on their tracker's nightly score, whose pursuit of a better number had itself become a source of the sleep-disrupting anxiety they came in for. A device sold to fix sleep anxiety, in other words, produced a documented clinical case of causing it. Between those two groups sits a much larger, quieter one: people spending on trackers, mattresses, and supplements instead of pursuing cognitive behavioral therapy for insomnia, which carries the strongest evidence of anything discussed here but is also the hardest of all of it to find, since it depends on a trained provider rather than a checkout page.